Send to

Choose Destination
Epigenomics. 2015;7(4):641-52. doi: 10.2217/epi.15.16.

Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.

Author information

Department of Medicine, Hematology/Oncology Division, University of California, San Francisco, CA 94115, USA.


Understanding the contribution of dysregulated gene silencing to epigenomic alterations in cancer development provides the rationale for the use of epigenetic modulators, such as histone deacetylase (HDAC) inhibitors, in cancer therapy. HDAC inhibitors have been approved as single agents for cutaneous and peripheral T-cell lymphoma and have shown promising activity in reversing therapy resistance in other tumor types. The effects of HDAC inhibitors on immune modulation have created a recent interest in their potential role in immunotherapy. This review describes the current understanding on integrating HDAC inhibitors into various immunotherapeutic approaches, such as cancer vaccines, adoptive T-cell transfer and immune checkpoint inhibitors. Furthermore, it summarizes promising treatment strategies in epigenetic immune priming from clinical trials that are currently underway.


HDAC inhibitors; adoptive T-cell transfer; cancer; epigenetics; immune checkpoint inhibitors; immune response; immunotherapy; vaccines

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center